# Ilan Zipkin

> Ilan Zipkin is a Series A investor at Aditum Bio (Palo Alto) backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aditum Bio](https://shizune.co/investors/profile/aditum-bio)
- Location: Palo Alto, United States
- Total investments: 5
- Last investment: Apr 2017
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ilan-zipkin-4729962
- X (Twitter): https://twitter.com/izipkin

Ilan Zipkin is a Series A investor at Aditum Bio in Palo Alto focused on Health Care and Biotechnology. Ilan Zipkin is the Partner and VP, Business Development and Licensing at Aditum Bio. She attended University of California, San Francisco.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 80% |
| Biotechnology | 4 | 80% |
| Therapeutics | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 80% |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |
| Debt Financing | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Canada | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $8M | Debt Financing | Apr 14, 2017 |  |
| Bioniz Therapeutics | Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approvaland commercialization.At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors.It was founded in 2009 and headquartered in Irvine, California. | $13M | Series A | Aug 01, 2016 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $15M | Series A | Jan 06, 2016 |  |
| Encycle Therapeutics | Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation,and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein. | $2.1M |  | Sep 30, 2015 |  |
| VHSquared | VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.Their novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases.There has been an explosion of interest in foods that haveadditional physiological benefits.VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the GI mucosal interface harnessing recent technological developments, including analysis of the microbiota and advances in mucosal immunology.Conventional antibodies are degraded in the gut and therefore efficacy obtained from oral administration is limited. VHsquared uses domain antibodies that can be selected and engineered to resist degradation, are intrinsically very stable and are locally active in the gastrointestinal tract.Products will offer advantages in terms of specificity, safety, efficacy, convenience and cost. |  | Series A | Dec 30, 2013 |  |

5 of 5 investments shown.

## Co-investors
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 2 deals together
- [Pfizer](https://shizune.co/investors/profile/pfizer) — VC Fund, 2 deals together
- [BDC Capital Corporation](https://shizune.co/investors/profile/bdc-capital-corporation) — VC Fund, 1 deal together
- [Breakout Ventures](https://shizune.co/investors/profile/breakoutventures) — VC Fund, 1 deal together
- [Lamond Family](https://shizune.co/investors/profile/lamond-family) — VC Fund, 1 deal together
- [Lundbeckfonden Ventures](https://shizune.co/investors/profile/lundbeckfond-ventures) — VC Fund, 1 deal together

## About Aditum Bio

VC Fund · San Francisco, United States

Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.

4 contacts available at Aditum Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Joe Jimenez | Co-Founder and Managing Director | https://shizune.co/investors/profile/joe-jimenez |
| Ilan Zipkin | Partner and VP, Business Development and Licensing | https://shizune.co/investors/profile/ilan-zipkin |
| Mark Fishman | Co-Founder and Chair of the Scientific Advisory BoardAditum Bio | https://shizune.co/investors/profile/mark-fishman-ce1a |
| Susie Phillips | Executive Assistant to Co-Founder and Managing Director | https://shizune.co/investors/profile/susie-phillips |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ilan Zipkin invest in?

Ilan Zipkin invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ilan Zipkin last invest?

The most recent investment recorded for Ilan Zipkin closed in Apr 2017. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co